Table 1 Demographic and clinical characteristics of patients by diabetic status and type of treatment
| Â | No diabetes mellitus | Diabetes mellitus non insulin-treated | Diabetes mellitus insulin-treated | p-value |
|---|---|---|---|---|
N = 603 | N = 132 | N = 42 | ||
Male gender | 519 (86.1) | 116 (87.9) | 38 (90.5) | 0.7 |
Age (years) | 58.9 ± 11.2 | 63.4 ± 10.4 | 62.8 ± 10.5 | <0.001 |
Body mass index (Kg/m2) | 28.1 ± 4.2 | 29.2 ± 4.5 | 29.2 ± 5.7 | 0.01 |
Dyslipidemia | 300 (49.8) | 72 (54.5) | 19 (45.2) | 0.5 |
Hypertension | 286 (47.4) | 94 (71.2) | 21 (50.0) | <0.001 |
Current smoking | 39 (6.5) | 4 (3.0) | 2 (4.8) | 0.3 |
Prior myocardial infarction | 45 (7.5) | 10 (7.6) | 4 (9.5) | 0.8 |
Prior CABG | 9 (1.5) | 2 (1.5) | 2 (4.8) | 0.3 |
Prior PCI | 58 (9.6) | 12 (9.1) | 4 (9.5) | 1.0 |
Prior stroke/TIA | 10 (1.7) | 6 (4.5) | 1 (2.4) | 0.2 |
Admission for PCI | Â | 0.2 | ||
STEMI | 342 (56.7) | 63 (47.7) | 26 (61.9) | Â |
NSTEMI | 161 (26.7) | 40 (30.3) | 7 (16.7) | Â |
Unstable angina | 100 (16.6) | 29 (22.0) | 9 (21.4) | Â |
Creatinine clearance <60Â ml/min | 51 (8.5) | 18 (13.6) | 11 (26.2) | 0.001 |
P2Y12 receptor blocker at discharge and follow-up | 0.7 | |||
Ticagrelor | 363 (60.2) | 76 (57.6) | 23 (54.8) | Â |
Prasugrel | 240 (39.8) | 56 (42.4) | 19 (45.2) | Â |
Other discharge medication* | ||||
Aspirin 100Â mg | 598 (99.2) | 131 (99.2) | 42 (100) | 1.0 |
Statin | 595 (98.7) | 128 (97.0) | 40 (95.2) | 0.09 |
Proton pump inhibitor | 572 (94.9) | 120 (90.9) | 34 (81.0) | 0.002 |
Beta-blocker | 565 (93.7) | 121 (91.7) | 40 (95.2) | 0.7 |
Nitrate | 66 (10.9) | 20 (15.2) | 8 (19.0) | 0.1 |